NCT01319240View on ClinicalTrials.gov

Safety and Tolerability of Insulin Degludec/Liraglutide (A3) in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions
DiabetesHealthy
Interventions
DRUG

insulin degludec

Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.

DRUG

insulin degludec/liraglutide

Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.

DRUG

liraglutide

Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.

Trial Locations (1)

41460

Neuss

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY